目的：基于国内多中心数据建立和验证一个预测肝内胆管癌（ICC）术后总体生存（OS）的列线图模型，并基于该预测模型筛选辅助化疗的受益人群。方法：回顾性收集2011年12月至2017年12月我国4家医疗单位278例术后病理学诊断为ICC病人的数据。采用COX回归模型筛选影响OS的独立风险因素并构建列线图模型。使用该模型对所有病人进行OS危险分层，筛选辅助化疗受益人群。结果：共纳入278例，其中23例（8.3%）接受辅助化疗。COX多因素分析显示：饮酒史、ECOG评分、肝切除方式、淋巴结状态、肿瘤数量以及肿瘤分化程度是影响术后OS的独立风险因素。列线图模型在训练集及验证集的一致性指数分别为0.690（95%CI：0.646~0.734）和0.740（95%CI：0.863~0.617）。根据列线图模型的危险分层，在高风险组，辅助化疗组与未辅助化疗组的生存差异有统计学意义（P=0.033），而在低风险组，生存差异无统计学意义（P=0.59）。结论：基于影响OS的独立风险因素建立的列线图模型具有良好的生存预测能力，可用于筛选受益于辅助化疗的ICC病人。

Objective To establish and validate a Nomogram model for predicting the overall survival (OS) of the patients with intrahepatic cholangiocarcinoma (ICC) based on domestic multicenter data, and screen the beneficiaries of adjuvant chemotherapy based on the prediction model. Methods From December 2011 to December 2017, the data of 278 patients with postoperative pathological diagnosis of ICC from 4 medical centers in our country were collected retrospectively COX regression model was used to screen the independent risk factors of OS and constructed a Nomogram model. This model was used to stratify the risk of OS for all patients and to screen the beneficiaries of adjuvant chemotherapy. Results A total of 278 patients were enrolled, and 23 cases(8.3%) received adjuvant chemotherapy. COX multivariate analysis showed that drinking history, ECOG score, method of hepatectomy, lymph node status, number of tumors, and tumor differentiation were independent risk factors for postoperative OS. The Nomogram model had a C-index of 0.690(95% CI: 0.646-0.734) in the training cohort and 0.740(95% CI: 0.863-0.617) in the validation cohort. According to risk stratification by Nomogram model, in the high-risk group there was a statistically significant difference in survival between adjuvant chemotherapy and non-adjuvant chemotherapy (P=0.033), whereas in the low-risk group, there was no significant difference in survival(P=0.59). Conclusion Nomogram model based on independent risk factors of OS demonstrated excellent predictive capability for survival and could be used to screen, and identify the patients with ICC who benefit from adjuvant chemotherapy.